Molecular targeted therapy for hepatocellular carcinoma: current and future

Area of Science:

• Hepatology and Oncology
• Molecular Biology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a prevalent global cancer, frequently developing in patients with chronic liver disease.
• Despite surveillance, HCC is often diagnosed at advanced stages, with poor prognosis due to resistance to conventional therapies.
• Sorafenib, a targeted therapy, offers a new direction but has limited efficacy, necessitating further research.

Purpose of the Study:

• To review current research on targeting molecular pathways in hepatocarcinogenesis.
• To summarize efforts in developing molecular targeted agents for HCC treatment.
• To discuss future research perspectives for advanced HCC.

Main Methods:

• Literature review of studies on molecular targeted agents for HCC.
• Analysis of signaling pathways involved in hepatocarcinogenesis.
• Assessment of ongoing clinical development phases for novel HCC therapies.

Main Results:

• Numerous molecular targeted agents are in clinical development, targeting various pathways crucial for HCC growth.
• Novel molecular targets are continuously being identified and assessed for HCC treatment efficacy.
• The review synthesizes current strategies for molecularly targeting HCC progression.

Conclusions:

• Targeting molecular pathways represents a critical area for advancing HCC treatment.
• Further research into novel molecular agents and targets is essential to overcome sorafenib's limitations.
• Future directions involve exploring new therapeutic strategies to improve outcomes for advanced HCC patients.